186826-86-8

  • Product Name:Moxifloxacine Hcl
  • Molecular Formula:C21H24FN3O4.ClH
  • Purity:99%
  • Molecular Weight:437.899
Inquiry

Product Details:

CasNo: 186826-86-8

Molecular Formula: C21H24FN3O4.ClH

Appearance: 99%

Quality Factory Supply 186826-86-8 Reasonable Price, Sale Moxifloxacine Hcl

  • Molecular Formula:C21H24FN3O4.ClH
  • Molecular Weight:437.899
  • Appearance/Colour:99% 
  • Vapor Pressure:4.56E-17mmHg at 25°C 
  • Melting Point:Slightly yellow to yellow crystalline powder, mp 324-325° 
  • Boiling Point:636.4 °C at 760 mmHg 
  • Flash Point:338.7 °C 
  • PSA:83.80000 
  • LogP:3.56630 

Moxifloxacin hydrochloride(Cas 186826-86-8) Usage

Description

Moxifloxacin Hydrochloride is the hydrochloride salt of moxifloxacin, a fluoroquinolone antibiotic. Fluoroquinolones are a class of antibiotics that target bacterial DNA gyrase (topoisomerase II) and topoisomerase IV enzymes, thereby inhibiting DNA replication, repair, and ultimately leading to bacterial cell death.

Chemical Properties

Light yellow to yellow crystalline powder

Originator

Bayer (Germany)

Uses

Treatment of Bacterial Infections: Moxifloxacin Hydrochloride is used to treat bacterial infections affecting various parts of the body, including respiratory tract infections, skin and soft tissue infections, intra-abdominal infections, and urinary tract infections. It is effective against a wide range of gram-positive and gram-negative bacteria.

Treatment and Prevention of Plague: Moxifloxacin Hydrochloride is also indicated for the treatment and prevention of plague, including pneumonic (lung) and septicemic (bloodstream) forms of the disease. Plague is a severe bacterial infection caused by Yersinia pestis, and moxifloxacin is one of the antibiotics recommended for its treatment.

Mechanism of Action: Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, which are essential for DNA replication and repair in bacteria. By interfering with these processes, moxifloxacin disrupts bacterial growth and ultimately leads to bacterial cell death.

InChI:InChI=1/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H

186826-86-8 Relevant articles

Preparation method of quinolone carboxylic acid derivative or phthalazinone carboxylic acid derivative

-

, (2021/10/27)

The invention belongs to the field of ph...

Sensitive Determination of Moxifloxacin HCl in Pharmaceuticals or Human Plasma Using Luminescence or Eye Vision

Gasser M. Khairy 1,*ORCID,Zaitona A. Abd El-Naby 2,Alaa M. A. Elgindy 2,Axel Duerkop 3,*ORCID andEman A. Abdel Hameed 4

, Chemosensors 2022, 10(10), 378;

A new probe based on the complex of 1,2 dihydro-2-oxoquinoloine-4-carboxylic acid (DOCA) as a ligand with Europium (III) ion was developed for the quantitation of Moxifloxacin HCl (Moxi.HCl) in pharmaceuticals and human plasma using a luminescence method. The metal to ligand ratio of the complex is 1:2 as determined by a Job plot. The determination of Moxi.HCl is based on static quenching of the luminescence of the probe upon coordination of Moxi.HCl.

Validated spectrophotometric methods for the estimation of moxifloxacin in bulk and pharmaceutical formulations

Sanjay K. Motwani, Shruti Chopra 1, Farhan J. Ahmad 1, Roop K. Khar 1

, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy Volume 68, Issue 2, October 2007, Pages 250-256

Moxifloxacin is a fourth generation 8-methoxy fluoroquinolone derivative [1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-{(4aS,7aS–octa-hydro-6H-pyrrolol (3,4b) pyridin-6-yl)}-4-oxo-3-quinoline carboxylic acid, monohydrochloride] with extended-spectrum and improved activity against Gram-positive bacteria (including staphylococci, streptococci, enterococci), anaerobes and atypical bacteria

186826-86-8 Process route

(4aS-cis)-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid-O<sup>3</sup>,O<sup>4</sup>(bis(acyloxy-O)) borate

(4aS-cis)-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid-O3,O4(bis(acyloxy-O)) borate

moxifloxacin hydrochloride
186826-86-8,1246654-75-0,1346603-25-5

moxifloxacin hydrochloride

Conditions
Conditions Yield
With hydrogenchloride; In methanol; water; at 0 - 8 ℃; for 0.333333h; Temperature;
96.2%
With hydrogenchloride; In water; at 0 ℃; for 4h; pH=< 1;
96.5%
With hydrogenchloride; In methanol; at -5 - 20 ℃; for 2h; pH=1; Temperature;
93.1%
With sodium hydroxide; In acetone; for 1h; Large scale;
89.8%
With sodium hydroxide; at 80 ℃; for 2.5h;
84.75%
With hydrogenchloride; In water; at 10 - 15 ℃; for 6h; pH=1.0 - 2.0;
118 g
With hydrogenchloride; In ethanol; water; at 25 ℃; for 1h; pH=1; Temperature;
48 g
1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
112811-72-0

1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid

(1S,6S)-2,8-diazabicyclo[4.3.0]nonane
151213-40-0,158060-81-2,169533-56-6

(1S,6S)-2,8-diazabicyclo[4.3.0]nonane

moxifloxacin hydrochloride
186826-86-8,1246654-75-0,1346603-25-5

moxifloxacin hydrochloride

Conditions
Conditions Yield
1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid; (1S,6S)-2,8-diazabicyclo[4.3.0]nonane; With titanium(IV) isopropylate; triethylamine; In isopropyl alcohol; at 100 ℃; Inert atmosphere;
With hydrogenchloride; In methanol; at 20 ℃; for 1h; pH=1; Solvent; Reagent/catalyst;
90%
Multi-step reaction with 2 steps
1: Alkaline conditions
2: hydrogenchloride
With hydrogenchloride;
 
1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid; (1S,6S)-2,8-diazabicyclo[4.3.0]nonane; With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetonitrile; at 20 - 85 ℃; for 36h; Inert atmosphere;
With hydrogenchloride; In water; at 15 ℃; for 1h; pH=1.4 - 1.8; Inert atmosphere;
3.3 g

186826-86-8 Upstream products

  • 151213-40-0
    151213-40-0

    (1S,6S)-2,8-diazabicyclo[4.3.0]nonane

  • 151096-09-2
    151096-09-2

    moxifloxacin

  • 192927-63-2
    192927-63-2

    1-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid monohydrochloride monohydrate

  • 496919-99-4
    496919-99-4

    1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline-carboxylic acid O3,O4-bis(propyloxy-O)borate

186826-86-8 Downstream products

  • 151096-09-2
    151096-09-2

    moxifloxacin

Relevant Products